首页>投融资
Amygdala Neurosciences
股权融资
Amygdala Neurosciences is a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders.In November 2019, the company closed US $5.6 million financing for development of ANS-6637
基本信息
-
公司全称Amygdala Neurosciences Inc
-
类型成瘾治疗药物研发商
-
产业领域研发制造服务、生物/化学技术、化学药
-
公司人数15~50人
-
地址509 Hale St PALO ALTO CALIFORNIA 94301-2210; US; Telephone: +16507140553;
-
联系电话858-707-5352
-
邮箱mailroom@amygns.com
-
成立时间2015-01-01
投融资
-
2024-05-14股权融资未透露未透露
-
2023-08-01捐赠/众筹/授予200万美元National Institute on Alcohol Abuse and Alcoholism
-
2019-11-18未透露560万美元National Institutes of HealthUnited States Department of Defense
-
2019-10-21捐赠/众筹/授予135万美元National Institutes of Health
- 加载更多
相关投融资企业
种子轮
Cypris Therapeutics是一家药物发现公司，在合成化学技术取得突破后推出，该技术允许开发用于治疗治疗耐药性疾病（包括脑癌和胰腺癌）的新型化学物质。该公司的专有技术能够合成和迭代研究人员以前无法实现的复杂小分子部分。
股权融资
Amygdala Neurosciences is a biopharmaceutical company focused on the development and commercialization of first-in-class drug candidates for addiction disorders.In November 2019, the company closed US $5.6 million financing for development of ANS-6637
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息